Gynecomastia Surgery
Customize your policy alerts
Sign up for Cigna Policy 0195 alerts
Get alerted when Policy 0195 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for mastectomy, reduction mammoplasty, and liposuction (including ultrasonic-assisted) when used to treat gynecomastia for members of Cigna-administered health benefit plans.
No material clinical or coverage changes in this revision.
Coverage Criteria for Surgical Treatment of Gynecomastia
Mastectomy or Reduction Mammoplasty - Medically Necessary Indications
Covered when ANY of the following are met:
Based on policy statement 1.a and 1.b
All seven items i-vii required per policy
Liposuction / Ultrasonically-Assisted Liposuction
Coverage stance:
Policy explicitly disallows liposuction alone (see CPT 15877 listed as not medically necessary when sole treatment).
Cosmetic and Other Non-covered Indications
Policy statements 3.a and 3.b
Policy statement 2
Not accepted as sole treatment for true gynecomastia
Coverage stance regarding suction-assisted and ultrasound-assisted liposuction
Literature mainly consists of small case series (n=13-61); liposuction removes adipose tissue but not glandular tissue.
Suction-assisted lipectomy (liposuction) (CPT 15877) and ultrasound-assisted suction lipectomy, when performed as the sole method of treatment for gynecomastia, are excluded and considered not medically necessary. The policy explicitly disallows liposuction-only approaches as a standalone treatment modality for true gynecomastia because these techniques remove adipose tissue but do not remove glandular breast tissue required to correct the condition.
The policy rationale states that suction-assisted and ultrasound-assisted liposuction are not accepted as sole treatments for true gynecomastia because these methods primarily remove adipose tissue and do not reliably excise glandular breast tissue. Peer-reviewed evidence supporting liposuction-only approaches is limited (mostly small case series), and therefore these techniques are not considered acceptable alternatives to standard surgical approaches for removing glandular tissue.
Mastectomy or reduction mammoplasty performed for indications other than those specifically listed as medically necessary in this policy are considered not medically necessary. Similarly, procedures that rely solely on liposuction techniques (including CPT 15877) as the only treatment for gynecomastia are explicitly not covered. Surgery performed solely for cosmetic reasons or solely to address psychological complaints is also classified as cosmetic and not covered.
As reiterated in the policy, suction-assisted lipectomy and ultrasound-assisted suction lipectomy may be used as adjuncts in selected cases but, when proposed as the sole method of treatment for true gynecomastia, they are not supported as adequate treatments because they do not remove glandular tissue. Providers proposing liposuction-only approaches should note the limited evidence base and that such claims may be denied or considered not medically necessary.
Coding and Timeframe Criteria
| 19300 | Mastectomy for gynecomastia |
| 15877 | Suction assisted lipectomy; trunk |
| No codes listed |
Provider Requirements, Documentation, and Authorization
Prior authorization required; CPT 19300 covered when criteria met
Submit prior authorization for surgical procedures billed with the policy-listed CPT codes. CPT 19300 (mastectomy for gynecomastia) is considered medically necessary when the policy criteria are met; CPT 15877 (suction-assisted lipectomy) is listed as not medically necessary when performed as the sole method of treatment.
Provide justification if liposuction-only approach is planned
When liposuction or ultrasound-assisted liposuction is proposed as the sole treatment for gynecomastia, include clinical justification and supporting documentation with the authorization request because these approaches are not considered acceptable alternatives for removal of glandular tissue.
- Prior authorization is implied for surgical management decisions when liposuction-only is proposed.
- Provide rationale and supporting literature if liposuction/ultrasound-assisted liposuction is submitted as sole therapy.
Require documented conservative management before surgery
Document and confirm that conservative management was attempted and documented prior to surgery, including discontinuation of causative drugs/substances when appropriate, correction/treatment of hormonal causes, and trial of medical therapy as applicable.
- Discontinue identified gynecomastia-inducing drugs/substances for at least one year when medically appropriate.
- Treat or exclude hormonal causes and, if treated, ensure treatment for at least 12 months before considering surgery.
- Document any trial of targeted medical therapy and correction of underlying causes.
No additional advisory specified
No specific provider action specified in the policy for this item.
Submit photos and exam/imaging showing glandular tissue and grade
Include preoperative frontal and lateral photographs and documentation demonstrating glandular breast tissue on physical exam and/or mammography to support the presence of at least Grade II gynecomastia.
- Preoperative frontal and lateral photographs confirming at least ASPS Grade II.
- Physical exam and/or mammography documenting glandular breast tissue (true gynecomastia).
Provide lab tests and documentation of hormonal management
Provide laboratory testing to exclude or document treatment of hormonal causes (e.g., TSH, estradiol, prolactin, testosterone, LH) and document management of identified endocrinopathies.
- Include results of TSH, estradiol, prolactin, testosterone and/or LH as applicable.
- Document duration and details of endocrine treatment if a hormonal cause was identified.
Document adipose vs glandular tissue and rationale when liposuction used alone
If liposuction (suction-assisted or ultrasound-assisted) is submitted as the sole treatment modality, document the extent of adipose versus glandular tissue and provide the clinical rationale recognizing that liposuction removes only adipose tissue and not glandular tissue.
- Demonstrate proportion of adipose vs glandular tissue on exam/imaging.
- Explain rationale for choosing liposuction-only despite policy noting it does not remove glandular tissue.
Claims missing covered codes or for non-covered indications are at risk of denial
Claims for procedures that are not accompanied by a covered diagnosis or the procedure codes listed in this policy, or for procedures determined not medically necessary (e.g., liposuction as sole treatment; mastectomy/reduction for non-listed indications), are subject to denial.
- Ensure procedure and diagnosis codes correspond to policy-listed covered indications.
- Avoid billing for mastectomy/reduction mammoplasty for indications outside the medically necessary criteria.
- Do not bill liposuction (CPT 15877) as the sole treatment for true gynecomastia if seeking coverage.
High denial risk for liposuction-only treatment of true gynecomastia
Claims for suction-assisted or ultrasound-assisted liposuction submitted as the sole method to treat true gynecomastia may be denied because these methods do not remove glandular tissue and are not considered acceptable alternatives to standard surgical approaches.
- Liposuction-only approaches remove adipose tissue but not glandular tissue; policy states they are not well-supported and may be denied.
- Provide alternative operative approach documentation if glandular removal is intended.
Background and Evidence Summary
Gynecomastia is a benign proliferation of glandular breast tissue in males and is distinct from pseudogynecomastia, which is enlargement due to adipose deposition without glandular proliferation. It commonly occurs during periods of physiologic hormonal fluctuation (for example, puberty) and often regresses spontaneously within one year in adolescents; persistent or higher-grade disease (ASPS Grade II–IV) is less likely to resolve and may require surgical intervention. Klinefelter syndrome is identified as a congenital cause associated with progressive gynecomastia and an increased breast cancer risk.
Definitions and Grading
Policy Revision History
Annual review — no clinical policy statement changes noted; policy effective date 2026-08-15.
Annual review — no clinical policy statement changes noted.
Annual review — no clinical policy statement changes noted.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.